Two mutations central to the development of infantile myofibromatosis (IM) — a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers.
Two mutations central to the development of infantile myofibromatosis (IM) — a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers.